The Journal of Pediatrics
Volume 150, Issue 6 , Pages 587-591, June 2007

Growth Hormone Treatment and Left Ventricular Dimensions in Turner Syndrome

  • Lea Ann Matura, PhD

      Affiliations

    • Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD
    • Corresponding Author InformationReprint requests: Dr. Lea Ann Matura, National Institutes of Health, CRC 1-3330, 10 Center Drive, Bethesda, MD 20892.
    • ,
  • Vandana Sachdev, MD

      Affiliations

    • National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD.
    • ,
  • Vladimir K. Bakalov, MD

      Affiliations

    • Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD
    • ,
  • Douglas R. Rosing, MD

      Affiliations

    • National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD.
    • ,
  • Carolyn A. Bondy, MD

      Affiliations

    • Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD

Received 18 October 2006; received in revised form 6 December 2006; accepted 1 February 2007.

Objective

To determine whether cardiac dimensions were different in girls with Turner syndrome (TS) who received growth hormone (GH) compared with those who did not receive GH.

Study design

This retrospective, cross-sectional study analyzed echocardiograms in 86 females with TS divided into GH-treated (n = 67) and untreated (n = 19) groups. The subjects all participated in the National Institutes of Health protocol between 2001 and 2006.

Results

The average age was 16.2 years (range, 10 to 25 years), and average duration of GH treatment was 4.4 years (range, 1 to 14 years). The GH-treated group was taller by ∼7 cm (P = .004), but cardiac dimensions normalized to body surface area (BSA), including septal and posterior wall thickness and left ventricular (LV) mass and internal diameters, did not differ significantly between the 2 groups. The fractional shortening index was similar in the 2 groups. Multiple regression analyses indicated that BSA, but not duration of GH treatment, predicted LV dimensions in girls with TS.

Conclusions

GH treatment of girls with TS increases stature but does not disproportionately affect cardiac dimensions.

Abbreviations: BSA, Body surface area, GH, Growth hormone, IVS, Interventricular septal thickness, LV, Left ventricular, LVIDD, Left ventricular internal diastolic dimension, LVM, Left ventricular mass, PW, Posterior wall thickness, TS, Turner syndrome

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by the intramural research program of the National Institute of Child Health and Human Development, National Institutes of Health.The authors have nothing to disclose and have no potential conflict of interest, real or perceived, to report. Lea Ann Matura wrote the first draft of the manuscript. No one involved in the production of the manuscript received any honorarium, grant, or other form of payment.

PII: S0022-3476(07)00127-8

doi:10.1016/j.jpeds.2007.02.009

Refers to article:

  • Focus on the Heart and Aorta in Turner Syndrome

    Angela E. Lin, Michael Silberbach
    The Journal of Pediatrics June 2007 (Vol. 150, Issue 6, Pages 572-574)

The Journal of Pediatrics
Volume 150, Issue 6 , Pages 587-591, June 2007

Article Tools